Pulmonary Medicine
-
ADVANCE OUTCOMES Trial: Ralinepag Reduces Clinical Worsening in Pulmonary Arterial Hypertension
A new phase 3 trial published in The Lancet suggests that ralinepag, an oral once-daily selective prostacyclin IP receptor agonist, can substantially reduce the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH) already receiving contemporary background therapy. The ADVANCE OUTCOMES trial evaluated whether adding ralinepag to existing PAH treatment could improve long-term…